Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2), By Region, Competition
The Global Kidney Cancer Drugs Market achieved a valuation of USD 6.28 Billion in 2022, and it is expected to experience substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.50% and is expected to reach USD 9.18 Billion by 2028. Kidney cancer, medically known as renal cell carcinoma (RCC), is a complex disease originating in the kidneys, vital organs responsible for filtering waste and excess fluids from the blood to produce urine. The treatment of kidney cancer is a challenging task, demanding effective strategies. The growth and evolution of the kidney cancer drugs market are being propelled by several key drivers as medical research advances and pharmaceutical innovation accelerates.
Key Market Drivers:
1. Advancements in Research and Development: Significant resources are being invested by pharmaceutical companies, academic institutions, and research organizations to gain a deep understanding of the underlying biology of kidney cancer. This investment has led to the identification of crucial molecular pathways, genetic mutations, and biomarkers responsible for driving the development and progression of kidney cancer. These advancements have laid the foundation for the development of targeted therapies, which focus on inhibiting specific molecules or pathways involved in cancer growth. Examples include tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, which have transformed kidney cancer treatment by providing more effective and less toxic therapies.
2. Immunotherapy Revolution: The advent of immunotherapies has brought about a revolution in the treatment of various cancers, including kidney cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy by harnessing the body's immune system to recognize and attack cancer cells. These therapies have not only extended survival rates but have also paved the way for innovative combination therapies. Researchers are actively exploring how to synergize targeted therapies with immunotherapies to achieve even more robust responses. The emergence of immunotherapies has ushered in a new era of cancer treatment.
3. Rising Clinical Trial Innovation: Clinical trials are fundamental in evaluating the safety and efficacy of new kidney cancer drugs. Innovative trial designs, incorporating biomarker-driven endpoints and adaptive trial designs, are propelling drug development forward. Biomarker-driven trials enable the selection of patients most likely to respond to a particular therapy, while adaptive trial designs allow real-time modifications based on accumulating data, enhancing trial efficiency and decision-making.
Key Market Challenges:
1. Resistance and Treatment Heterogeneity: Despite the progress made in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Tumors can adapt over time, rendering once-effective therapies ineffective. This highlights the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Moreover, kidney cancer is not a homogeneous disease, with different subtypes and genetic variations contributing to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor.
2. Lack of Predictive Biomarkers: The absence of reliable predictive biomarkers hinders the development of effective kidney cancer drugs. Biomarkers that can accurately identify patients likely to respond to a particular treatment are essential for personalized medicine approaches. Currently, no single biomarker has demonstrated consistent predictive value across all patients and treatment modalities. The lack of reliable biomarkers makes it challenging for healthcare professionals to make informed treatment decisions.
3. Immune-Related Adverse Events (irAEs): Immunotherapies, while transformative in cancer treatment, can lead to immune-related adverse events (irAEs) as they activate the immune system. These events can affect various organs, necessitating careful management to balance immune activation against potential harm. The occurrence and severity of irAEs can impact patient compliance, quality of life, and overall treatment success.
Key Market Trends:
1. Personalized Medicine Revolution: The advent of personalized medicine is offering promising prospects for improved patient outcomes in kidney cancer treatment. Precision oncology tailors interventions based on individual genetic profiles and biomarker expression, moving away from a one-size-fits-all approach. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. This information guides the prescription of targeted therapies with a higher likelihood of success, enhancing drug efficacy and minimizing adverse effects.
2. Combination Therapies: Combining multiple treatments simultaneously or sequentially is emerging as a powerful strategy to enhance treatment efficacy and overcome resistance in kidney cancer. The synergy achieved by combining targeted therapies with immunotherapies or other treatment modalities offers a multifaceted approach to attacking cancer cells. The exploration of novel combinations that maximize treatment outcomes is driving the demand for kidney cancer drugs. The potential to achieve better responses and prolonged disease control is spurring collaborative efforts to identify the optimal synergy between different therapeutic approaches.
Segmental Insights:
Therapeutic Class Insights: In 2022, the immunotherapy segment dominated the Kidney Cancer Drugs Market, holding the largest share. The increasing preference for innovative immunotherapies and immune-oncologic drugs is driving the use of targeted therapies, particularly in specific patient subpopulations or as later lines of treatment, which is boosting demand.
Regional Insights: North America has established itself as the leader in the Global Kidney Cancer Drugs Market. This can be attributed to widespread healthcare spending and favorable reimbursement regulations for therapy. Furthermore, the high prevalence of smoking, hypertension, and diabetes among its population, along with the presence of major pharmaceutical manufacturers, positions Asia-Pacific to experience the highest growth in the kidney cancer drugs market during the forecast period.
Key Market Players
In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.
Available Customizations:
Global Kidney Cancer Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers:
1. Advancements in Research and Development: Significant resources are being invested by pharmaceutical companies, academic institutions, and research organizations to gain a deep understanding of the underlying biology of kidney cancer. This investment has led to the identification of crucial molecular pathways, genetic mutations, and biomarkers responsible for driving the development and progression of kidney cancer. These advancements have laid the foundation for the development of targeted therapies, which focus on inhibiting specific molecules or pathways involved in cancer growth. Examples include tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, which have transformed kidney cancer treatment by providing more effective and less toxic therapies.
2. Immunotherapy Revolution: The advent of immunotherapies has brought about a revolution in the treatment of various cancers, including kidney cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy by harnessing the body's immune system to recognize and attack cancer cells. These therapies have not only extended survival rates but have also paved the way for innovative combination therapies. Researchers are actively exploring how to synergize targeted therapies with immunotherapies to achieve even more robust responses. The emergence of immunotherapies has ushered in a new era of cancer treatment.
3. Rising Clinical Trial Innovation: Clinical trials are fundamental in evaluating the safety and efficacy of new kidney cancer drugs. Innovative trial designs, incorporating biomarker-driven endpoints and adaptive trial designs, are propelling drug development forward. Biomarker-driven trials enable the selection of patients most likely to respond to a particular therapy, while adaptive trial designs allow real-time modifications based on accumulating data, enhancing trial efficiency and decision-making.
Key Market Challenges:
1. Resistance and Treatment Heterogeneity: Despite the progress made in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Tumors can adapt over time, rendering once-effective therapies ineffective. This highlights the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Moreover, kidney cancer is not a homogeneous disease, with different subtypes and genetic variations contributing to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor.
2. Lack of Predictive Biomarkers: The absence of reliable predictive biomarkers hinders the development of effective kidney cancer drugs. Biomarkers that can accurately identify patients likely to respond to a particular treatment are essential for personalized medicine approaches. Currently, no single biomarker has demonstrated consistent predictive value across all patients and treatment modalities. The lack of reliable biomarkers makes it challenging for healthcare professionals to make informed treatment decisions.
3. Immune-Related Adverse Events (irAEs): Immunotherapies, while transformative in cancer treatment, can lead to immune-related adverse events (irAEs) as they activate the immune system. These events can affect various organs, necessitating careful management to balance immune activation against potential harm. The occurrence and severity of irAEs can impact patient compliance, quality of life, and overall treatment success.
Key Market Trends:
1. Personalized Medicine Revolution: The advent of personalized medicine is offering promising prospects for improved patient outcomes in kidney cancer treatment. Precision oncology tailors interventions based on individual genetic profiles and biomarker expression, moving away from a one-size-fits-all approach. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. This information guides the prescription of targeted therapies with a higher likelihood of success, enhancing drug efficacy and minimizing adverse effects.
2. Combination Therapies: Combining multiple treatments simultaneously or sequentially is emerging as a powerful strategy to enhance treatment efficacy and overcome resistance in kidney cancer. The synergy achieved by combining targeted therapies with immunotherapies or other treatment modalities offers a multifaceted approach to attacking cancer cells. The exploration of novel combinations that maximize treatment outcomes is driving the demand for kidney cancer drugs. The potential to achieve better responses and prolonged disease control is spurring collaborative efforts to identify the optimal synergy between different therapeutic approaches.
Segmental Insights:
Therapeutic Class Insights: In 2022, the immunotherapy segment dominated the Kidney Cancer Drugs Market, holding the largest share. The increasing preference for innovative immunotherapies and immune-oncologic drugs is driving the use of targeted therapies, particularly in specific patient subpopulations or as later lines of treatment, which is boosting demand.
Regional Insights: North America has established itself as the leader in the Global Kidney Cancer Drugs Market. This can be attributed to widespread healthcare spending and favorable reimbursement regulations for therapy. Furthermore, the high prevalence of smoking, hypertension, and diabetes among its population, along with the presence of major pharmaceutical manufacturers, positions Asia-Pacific to experience the highest growth in the kidney cancer drugs market during the forecast period.
Key Market Players
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Genentech Inc.
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- Exelixis Inc
- Prometheus Laboratories Inc
- Glaxosmithkline PLC.
- F. Hoffmann-LA Roche AG
In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Kidney Cancer Drugs Market, By Therapeutic Class:
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Kidney Cancer Drugs Market, By Pharmacologic Class:
- Angiogenesis Inhibitors
- Monoclonal Antibodies
- mTOR Inhibitors
- Cytokine Immunotherapy (IL-2)
- Global Kidney Cancer Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.
Available Customizations:
Global Kidney Cancer Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL KIDNEY CANCER DRUGS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
5.2.3. By Company (2022)
5.2.4. By Region
5.3. Market Map
6. NORTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Class
6.2.2. By Pharmacologic Class
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Kidney Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Class
6.3.1.2.2. By Pharmacologic Class
6.3.2. Mexico Kidney Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Class
6.3.2.2.2. By Pharmacologic Class
6.3.3. Canada Kidney Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Class
6.3.3.2.2. By Pharmacologic Class
7. EUROPE KIDNEY CANCER DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Therapeutic Class
7.2.2. By Pharmacologic Class
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Kidney Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Class
7.3.1.2.2. By Pharmacologic Class
7.3.2. Germany Kidney Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Class
7.3.2.2.2. By Pharmacologic Class
7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Class
7.3.3.2.2. By Pharmacologic Class
7.3.4. Italy Kidney Cancer Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Class
7.3.4.2.2. By Pharmacologic Class
7.3.5. Spain Kidney Cancer Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Class
7.3.5.2.2. By Pharmacologic Class
8. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Therapeutic Class
8.2.2. By Pharmacologic Class
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Kidney Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Class
8.3.1.2.2. By Pharmacologic Class
8.3.2. India Kidney Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Class
8.3.2.2.2. By Pharmacologic Class
8.3.3. South Korea Kidney Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Class
8.3.3.2.2. By Pharmacologic Class
8.3.4. Japan Kidney Cancer Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Class
8.3.4.2.2. By Pharmacologic Class
8.3.5. Australia Kidney Cancer Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Class
8.3.5.2.2. By Pharmacologic Class
9. SOUTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Class
9.2.2. By Pharmacologic Class
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Kidney Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Class
9.3.1.2.2. By Pharmacologic Class
9.3.2. Argentina Kidney Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Class
9.3.2.2.2. By Pharmacologic Class
9.3.3. Colombia Kidney Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Class
9.3.3.2.2. By Pharmacologic Class
10. MIDDLE EAST AND AFRICA KIDNEY CANCER DRUGS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Class
10.2.2. By Pharmacologic Class
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Kidney Cancer Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Class
10.3.1.2.2. By Pharmacologic Class
10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Class
10.3.2.2.2. By Pharmacologic Class
10.3.3. UAE Kidney Cancer Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Class
10.3.3.2.2. By Pharmacologic Class
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Novartis AG
15.6.2. Pfizer Inc.
15.6.3. Bayer AG
15.6.4. Genentech Inc.
15.6.5. Bristol-Myers Squibb
15.6.6. Eisai Co., Ltd.
15.6.7. Exelixis Inc
15.6.8. Prometheus Laboratories Inc
15.6.9. GlaxoSmithKline Plc
15.6.10. F. Hoffmann-LA Roche AG
16. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL KIDNEY CANCER DRUGS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
5.2.3. By Company (2022)
5.2.4. By Region
5.3. Market Map
6. NORTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Class
6.2.2. By Pharmacologic Class
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Kidney Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Class
6.3.1.2.2. By Pharmacologic Class
6.3.2. Mexico Kidney Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Class
6.3.2.2.2. By Pharmacologic Class
6.3.3. Canada Kidney Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Class
6.3.3.2.2. By Pharmacologic Class
7. EUROPE KIDNEY CANCER DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Therapeutic Class
7.2.2. By Pharmacologic Class
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Kidney Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Class
7.3.1.2.2. By Pharmacologic Class
7.3.2. Germany Kidney Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Class
7.3.2.2.2. By Pharmacologic Class
7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Class
7.3.3.2.2. By Pharmacologic Class
7.3.4. Italy Kidney Cancer Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Class
7.3.4.2.2. By Pharmacologic Class
7.3.5. Spain Kidney Cancer Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Class
7.3.5.2.2. By Pharmacologic Class
8. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Therapeutic Class
8.2.2. By Pharmacologic Class
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Kidney Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Class
8.3.1.2.2. By Pharmacologic Class
8.3.2. India Kidney Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Class
8.3.2.2.2. By Pharmacologic Class
8.3.3. South Korea Kidney Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Class
8.3.3.2.2. By Pharmacologic Class
8.3.4. Japan Kidney Cancer Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Class
8.3.4.2.2. By Pharmacologic Class
8.3.5. Australia Kidney Cancer Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Class
8.3.5.2.2. By Pharmacologic Class
9. SOUTH AMERICA KIDNEY CANCER DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Class
9.2.2. By Pharmacologic Class
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Kidney Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Class
9.3.1.2.2. By Pharmacologic Class
9.3.2. Argentina Kidney Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Class
9.3.2.2.2. By Pharmacologic Class
9.3.3. Colombia Kidney Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Class
9.3.3.2.2. By Pharmacologic Class
10. MIDDLE EAST AND AFRICA KIDNEY CANCER DRUGS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Class
10.2.2. By Pharmacologic Class
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Kidney Cancer Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Class
10.3.1.2.2. By Pharmacologic Class
10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Class
10.3.2.2.2. By Pharmacologic Class
10.3.3. UAE Kidney Cancer Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Class
10.3.3.2.2. By Pharmacologic Class
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Novartis AG
15.6.2. Pfizer Inc.
15.6.3. Bayer AG
15.6.4. Genentech Inc.
15.6.5. Bristol-Myers Squibb
15.6.6. Eisai Co., Ltd.
15.6.7. Exelixis Inc
15.6.8. Prometheus Laboratories Inc
15.6.9. GlaxoSmithKline Plc
15.6.10. F. Hoffmann-LA Roche AG
16. STRATEGIC RECOMMENDATIONS
